Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Advax, a Delta Inulin Microparticle, Potentiates In-built Adjuvant Property of Co-administered Vaccines.

Hayashi M, Aoshi T, Haseda Y, Kobiyama K, Wijaya E, Nakatsu N, Igarashi Y, Standley DM, Yamada H, Honda-Okubo Y, Hara H, Saito T, Takai T, Coban C, Petrovsky N, Ishii KJ.

EBioMedicine. 2017 Feb;15:127-136. doi: 10.1016/j.ebiom.2016.11.015.

2.
3.

Assaying the Potency of Influenza Vaccines.

Minor PD.

Vaccines (Basel). 2015 Feb 5;3(1):90-104. doi: 10.3390/vaccines3010090. Review.

4.

Wheeze as an adverse event in pediatric vaccine and drug randomized controlled trials: A systematic review.

Marangu D, Kovacs S, Walson J, Bonhoeffer J, Ortiz JR, John-Stewart G, Horne DJ.

Vaccine. 2015 Oct 5;33(41):5333-41. doi: 10.1016/j.vaccine.2015.08.060. Review.

5.

Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.

Winokur PL, Patel SM, Brady R, Chen WH, El-Kamary SS, Edwards K, Creech CB, Frey S, Keitel WA, Belshe R, Walter E, Bellamy A, Hill H.

J Infect Dis. 2015 Aug 15;212(4):525-30. doi: 10.1093/infdis/jiv087.

6.

AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.

Kosalaraksa P, Jeanfreau R, Frenette L, Drame M, Madariaga M, Innis BL, Godeaux O, Izurieta P, Vaughn DW.

J Infect Dis. 2015 Mar 1;211(5):801-10. doi: 10.1093/infdis/jiu548.

7.

Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study.

Roy-Ghanta S, Van der Most R, Li P, Vaughn DW.

J Infect Dis. 2014 Nov 1;210(9):1419-30. doi: 10.1093/infdis/jiu284.

8.

H5N1 vaccines in humans.

Baz M, Luke CJ, Cheng X, Jin H, Subbarao K.

Virus Res. 2013 Dec 5;178(1):78-98. doi: 10.1016/j.virusres.2013.05.006. Review.

9.

Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans.

Couch RB, Decker WK, Utama B, Atmar RL, Niño D, Feng JQ, Halpert MM, Air GM.

PLoS One. 2012;7(12):e50830. doi: 10.1371/journal.pone.0050830.

10.

Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age.

Vesikari T, Pepin S, Kusters I, Hoffenbach A, Denis M.

Hum Vaccin Immunother. 2012 Sep;8(9):1283-92. doi: 10.4161/hv.21265.

11.

Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older.

Ikematsu H, Tenjinbaru K, Li P, Madan A, Vaughn D.

Hum Vaccin Immunother. 2012 Aug;8(8):1119-25. doi: 10.4161/hv.21081.

12.

Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons.

Jackson LA, Chen WH, Stapleton JT, Dekker CL, Wald A, Brady RC, Edupuganti S, Winokur P, Mulligan MJ, Keyserling HL, Kotloff KL, Rouphael N, Noah DL, Hill H, Wolff MC.

J Infect Dis. 2012 Sep 15;206(6):811-20. doi: 10.1093/infdis/jis427.

13.

Seroprevalence of pandemic H1N1 antibody among health care workers in Hong Kong following receipt of monovalent 2009 H1N1 influenza vaccine.

Zhou Y, Ng DM, Seto WH, Ip DK, Kwok HK, Ma ES, Ng S, Lau LL, Peiris JS, Cowling BJ.

PLoS One. 2011;6(11):e27169. doi: 10.1371/journal.pone.0027169.

14.

Pandemic influenza vaccines - the challenges.

Haaheim LR, Madhun AS, Cox R.

Viruses. 2009 Dec;1(3):1089-109. doi: 10.3390/v1031089.

15.

Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults.

Lasko B, Reich D, Madan A, Roman F, Li P, Vaughn D.

J Infect Dis. 2011 Aug 15;204(4):574-81. doi: 10.1093/infdis/jir328.

16.

Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets.

Layton RC, Petrovsky N, Gigliotti AP, Pollock Z, Knight J, Donart N, Pyles J, Harrod KS, Gao P, Koster F.

Vaccine. 2011 Aug 26;29(37):6242-51. doi: 10.1016/j.vaccine.2011.06.078.

17.

Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret.

Layton RC, Gigliotti A, Armijo P, Myers L, Knight J, Donart N, Pyles J, Vaughan S, Plourde J, Fomukong N, Harrod KS, Gao P, Koster F.

PLoS One. 2011;6(6):e20641. doi: 10.1371/journal.pone.0020641.

18.

Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study.

Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B, Fogarty C, Poling T, Riff D, Baron M, Frenette L, Sheldon E, Collins H, Shepard M, Dionne M, Brune D, Ferguson L, Vaughn D, Li P, Fries L.

J Infect Dis. 2011 Jun 15;203(12):1729-38. doi: 10.1093/infdis/jir172.

19.

Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials.

Roman F, Clément F, Dewé W, Walravens K, Maes C, Willekens J, De Boever F, Hanon E, Leroux-Roels G.

Clin Vaccine Immunol. 2011 May;18(5):835-43. doi: 10.1128/CVI.00480-10.

20.

Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England.

Andrews N, Waight P, Yung CF, Miller E.

J Infect Dis. 2011 Jan 1;203(1):32-9. doi: 10.1093/infdis/jiq014.

Supplemental Content

Support Center